Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Approximately 6.3 million bone fractures occur annually in the United States, resulting in considerable morbidity, deterioration in quality of life, loss of productivity and wages, and sometimes death (e.g., hip fractures). Although anabolic and antiresorptive agents have been introduced for treatment of osteoporosis, no systemically administered drug has been developed to accelerate the fracture-healing process. To address this need, we have undertaken to target a bone anabolic agent selectively to fracture surfaces in order to concentrate the drug's healing power directly on the fracture site. We report here that conjugation of dasatinib to a bone fracture-homing oligopeptide via a releasable linker reduces fractured femur healing times in mice by ∼60% without causing overt off-target toxicity or remodeling of nontraumatized bones. Thus, achievement of healthy bone density, normal bone volume, and healthy bone mechanical properties at the fracture site is realized after only 3-4 weeks in dasatinib-targeted mice, but it requires ∼8 weeks in PBS-treated controls. We conclude that targeting of dasatinib to bone fracture surfaces can significantly accelerate the healing process at dasatinib concentrations that are known to be safe in oncological applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acidic oligopeptides such as desatinib have been proposed for the acceleration of fracture healing, as their systemic side effects could be very low when targeted to the fracture site (selective drug delivery), while a strong effect on healing time is expected with local administration; however, clinical studies involving fracture patients are currently unavailable (86, 110).”
From Methods to accelerate fracture healing – a narrative review from a clinical perspective (2024) · cites this paper as [110]
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., & Müller, R. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.141 · Cited by 4,433
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
BoneJ: Free and extensible bone image analysis in ImageJ
Doube, M., Kłosowski, M. M., Arganda-Carreras, I., Cordelières, F. P., Dougherty, R. P., Jackson, J. S., Schmid, B., Hutchinson, J. R., & Shefelbine, S. J. (2010) · Bone · doi:10.1016/j.bone.2010.08.023 · Cited by 2,040
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
Estimating Hip Fracture Morbidity, Mortality and Costs
Braithwaite, R. S., Col, N. F., & Wong, J. B. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51110.x · Cited by 911
Mortality and morbidity after hip fractures.
Keene, G. S., Parker, M. J., & Pryor, G. A. (1993) · BMJ · doi:10.1136/bmj.307.6914.1248 · Cited by 876
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice.
Boyce, B. F., Yoneda, T., Lowe, C., Soriano, P., & Mundy, G. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116032 · Cited by 550
The Aftermath of Hip Fracture: Discharge Placement, Functional Status Change, and Mortality
Bentler, S. E., Liu, L., Obrizan, M., Cook, E. A., Wright, K. B., Geweke, J. F., Chrischilles, E. A., Pavlik, C. E., Wallace, R. B., Ohsfeldt, R. L., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp266 · Cited by 470
Jepsen, K. J., Silva, M. J., Vashishth, D., Guo, X. E., & van der Meulen, M. C. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2539 · Cited by 333
Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration
Zhang, Y., Desai, A., Yang, S. Y., Bae, K. B., Antczak, M. I., Fink, S. P., Tiwari, S., Willis, J. E., Williams, N. S., Dawson, D. M., et al. (2015) · Science · doi:10.1126/science.aaa2340 · Cited by 297
Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation
Marzia, M., Sims, N. A., Voit, S., Migliaccio, S., Taranta, A., Bernardini, S., Faraggiana, T., Yoneda, T., Mundy, G. R., Boyce, B. F., et al. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.311 · Cited by 284
Bishop, G. B., & Einhorn, T. A. (2007) · International Orthopaedics · doi:10.1007/s00264-007-0424-8 · Cited by 232
Zhao, W., Byrne, M. H., Boyce, B. F., & Krane, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5481 · Cited by 213
Adachi, J. D., Adami, S., Gehlbach, S., Anderson, F. A., Boonen, S., Chapurlat, R. D., Compston, J. E., Cooper, C., Delmas, P., Díez-Pérez, A., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0082 · Cited by 199
Kamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 191
Kulkarni, N. H., Onyia, J. E., Zeng, Q., Tian, X., Liu, M., Halladay, D. L., Frolik, C. A., Engler, T., Wei, T., Kriauciunas, A., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060316 · Cited by 182
Denosumab: A review in postmenopausal osteoporosis
Deeks, E. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0525-7 · Cited by 169
Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation
Kasugai, S., Fujisawa, R., Waki, Y., Miyamoto, K.-I., & Ohya, K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.936 · Cited by 161
Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature
Pavone, V., Testa, G., Giardina, S. M. C., Vescio, A., Restivo, D. A., & Sessa, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00803 · Cited by 154
Parathyroid Hormone Temporal Effects on Bone Formation and Resorption
Kroll, M. H. (2000) · Bulletin of Mathematical Biology · doi:10.1006/bulm.1999.0146 · Cited by 145
Cappariello, A., Loftus, A. E. P., Muraca, M., Maurizi, A., Rucci, N., & Teti, A. M. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3332 · Cited by 139
Anabolic Therapies in Osteoporosis and Bone Regeneration
Rußow, G., Jahn, D., Appelt, J., Märdian, S., Tsitsilonis, S., & Keller, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010083 · Cited by 135
Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss
Weske, S., Vaidya, M., Reese, A., Lipinski, K. V. W., Keul, P., Bayer, J. K., Fischer, J. W., Flögel, U., Nelsen, J., Epple, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0005-y · Cited by 131
Mediero, A., Wilder, T., Perez‐Aso, M., & Cronstein, B. N. (2015) · The FASEB Journal · doi:10.1096/fj.14-265066 · Cited by 103
Lee, D., Heo, D. N., Kim, H.-J., Ko, W.-K., Lee, S. J., Heo, M., Bang, J. B., Lee, J. B., Hwang, D.-S., Do, S. H., et al. (2016) · Scientific Reports · doi:10.1038/srep27336 · Cited by 103
Yokogawa, K., Miya, K., Sekido, T., Higashi, Y., Nomura, M., Fujisawa, R., Morito, K., Masamune, Y., Waki, Y., Kasugai, S., et al. (2001) · Endocrinology · doi:10.1210/endo.142.3.8024 · Cited by 102
Vandyke, K., Dewar, A. L., Diamond, P., Fitter, S., Schultz, C. G., Sims, N. A., & Zannettino, A. C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.85 · Cited by 88
Alemán, J. O., Farooki, A., & Girotra, M. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-12-0400 · Cited by 87
Bartl, R., & Frisch, B. (2009) · Springer eBooks · doi:10.1007/978-3-540-79527-8 · Cited by 83
Boufker, H. I., Lagneaux, L., Najar, M., Piccart, M. J., Ghanem, G., Body, J., & Journé, F. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-298 · Cited by 81
Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis
Shi, Z., Zhou, H., Pan, B., Lu, L., Liu, J., Kang, Y., Yao, X. X., & Feng, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168691 · Cited by 80
Lee, Y.-C., Huang, C.-F., Murshed, M., Chu, K., Araujo, J. C., Ye, X., deCrombrugghe, B., Yu-Lee, L.-Y., Gallick, G. E., & Lin, S.-H. (2010) · Oncogene · doi:10.1038/onc.2010.73 · Cited by 79
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor
Brownlow, N., Mol, C. D., Hayford, C., Ghaem‐Maghami, S., & Dibb, N. J. (2008) · Leukemia · doi:10.1038/leu.2008.237 · Cited by 77
Sekido, T., Sakura, N., Higashi, Y., Miya, K., Nitta, Y., Nomura, M., Sawanishi, H., Morito, K., Masamune, Y., Kasugai, S., et al. (2001) · Journal of drug targeting · doi:10.3109/10611860108997922 · Cited by 77
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
Garcia-Gomez, A., Ocio, E. M., Crusoe, E., Santamaria, C., Hernández-Campo, P., Blanco, J. F., Sanchez-Guijo, F. M., Hernández-Iglesias, T., Briñón, J. G., Fisac-Herrero, R. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034914 · Cited by 76
Surgery for Hip Fracture Yields Societal Benefits That Exceed the Direct Medical Costs
Gu, Q., Koenig, L., Mather, R. C. “., & Tongue, J. R. (2014) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-014-3820-6 · Cited by 72
The Role of BMPs in Bone Anabolism and their Potential Targets SOST and DKK1
Kamiya, N. (2012) · Current Molecular Pharmacology · doi:10.2174/1874-470211205020153 · Cited by 66
Lithium‐Associated Hypercalcemia: Pathophysiology, Prevalence, Management
Meehan, A. D., Udumyan, R., Kardell, M., Landén, M., Järhult, J., & Wallin, G. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4328-5 · Cited by 64
Estrogen therapy for postmenopausal osteoporosis
Fitzpatrick, L. A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400016 · Cited by 63
Use of Teriparatide to improve fracture healing: What is the evidence?
Babu, S., Sandiford, N. A., & Vrahas, M. (2015) · World Journal of Orthopedics · doi:10.5312/wjo.v6.i6.457 · Cited by 58
Selective drug delivery to bone using acidic oligopeptides
Ishizaki, J., Waki, Y., Nishioka, T., Yokogawa, K., & Miyamoto, K. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0004-z · Cited by 55
Dubrovsky, L., Pankov, D., Brea, E. J., Dao, T., Scott, A., Yan, S., O’Reilly, R. J., Liu, C., & Scheinberg, D. A. (2014) · Blood · doi:10.1182/blood-2014-01-549022 · Cited by 54
Kim, H., Choi, S., Yoon, J., Lim, H. J., Lee, H., Choi, J., Ro, E. J., Heo, J., Lee, W., No, K. T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505714 · Cited by 44
The economic burden of outpatient appointments following paediatric fractures
Holm, A. G. V., Lurås, H., & Randsborg, P. (2016) · Injury · doi:10.1016/j.injury.2016.04.007 · Cited by 40
Biodistribution of Fracture-Targeted GSK3β Inhibitor-Loaded Micelles for Improved Fracture Healing
Low, S. A., Galliford, C. V., Yang, J., Low, P. S., & Kopec̆ek, J. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00777 · Cited by 32
Self-citationAbaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
Chew, C. K., & Clarke, B. L. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.12.003 · Cited by 30
Wasnik, S., Lakhan, R., Baylink, D. J., Rundle, C. H., Xu, Y., Zhang, J., Qin, X., Lau, K. ‐. W., Berumen, E. C., & Tang, X. (2019) · Science Advances · doi:10.1126/sciadv.aaw2108 · Cited by 25
Severe hypercalcemia due to teriparatide
Karatoprak, C., Kayataş, K., Kilicaslan, H., Yolbaş, S., Yazimci, N., Gümüskemer, T., & Demirtunç, R. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.93869 · Cited by 24
Arangio, G. A., Lehr, S., & REED, J. F. (1997) · doi:10.1097/00005373-199705000-00027 · Cited by 23
Short Anabolic Peptides for Bone Growth
Amso, Z., Cornish, J., & Brimble, M. A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21388 · Cited by 21
Healing Efficacy of fracture-targeted GSK3β inhibitor-loaded Micelles for Improved Fracture Repair
Low, S. A., Galliford, C. V., Jones‐Hall, Y., Roy, J., Yang, J., Low, P. S., & Kopec̆ek, J. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0340 · Cited by 18
Self-citationBorriello, A., Caldarelli, I., Bencivenga, D., Stampone, E., Perrotta, S., Oliva, A., & Ragione, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12649 · Cited by 17
Jönsson, S., Hjorth‐Hansen, H., Olsson, B., Wadenvik, H., Sundan, A., & Standal, T. (2010) · Leukemia · doi:10.1038/leu.2010.84 · Cited by 14
Bio-Targets and Drug Delivery Approaches
Maiti, S., & Sen, K. K. (2016) · CRC Press eBooks · doi:10.1201/9781315370118 · Cited by 10
Li, J., & Stocum, D. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416015-6.00010-1 · Cited by 10
Research works printed but not linked: 3
- 10.2174/1874467211205020153 · doi:10.2174/1874467211205020153 · Paper page
- Peruzzi B., 2012, Protein Kinases, 357
- Dittmer D. K., 1993, Can. Fam. Physician Med. Fam. Can., 39, 1428
Cited by
Anabolic Therapies in Osteoporosis and Bone Regeneration
Rußow, G., Jahn, D., Appelt, J., Märdian, S., Tsitsilonis, S., & Keller, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010083 · Cited by 135
Innovative Linker Strategies for Tumor‐Targeted Drug Conjugates
Corso, A. D., Pignataro, L., Belvisi, L., & Gennari, C. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903127 · Cited by 125
Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis
Fu, J., Wang, Y., Jiang, Y., Du, J., Xu, J., & Liu, Y. F. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02456-w · Cited by 91
Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints
Martinis, M. D., Sirufo, M. M., & Ginaldi, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190730113123 · Cited by 84
Fluorescent Self‐Threaded Peptide Probes for Biological Imaging
Zhai, C., Schreiber, C. L., Padilla‐Coley, S., Oliver, A. G., & Smith, B. D. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202009599 · Cited by 83
Metadata
- Authors
- Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S.
- Affiliations
- Purdue University West Lafayette (US)
- Corresponding author
- Low, Philip S.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-10-31
- Volume
- 29
- Issue
- 11
- Pages
- 3800-3809
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2899187179
- Cited by
- 24
- References
- 58
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 1
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Bioconjugate Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- dasatinib, fracture healing, targeted drug delivery, femoral fracture, bone remodeling, bone mechanical properties, hip fracture
- MeSH terms
- Dasatinib, Animals, Aspartic Acid, Cell Line, Female, Oligopeptides, Quality of Life, Bone Density, Drug Delivery Systems, Fracture Healing, Protein Kinase Inhibitors, Fractures, Bone, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.